

Date: October 1, 2023

To Listing Department, <b>NATIONAL STOCK EXCHANGE OF INDIA LIMITED</b> Exchange Plaza, Bandra Kurla Complex, Bandra (E), <b>MUMBAI -400 051</b>	To The Corporate Relations Department <b>BSE LIMITED</b> Phiroz Jeejeebhoy Towers, 25th floor, Dalal Street, <b>MUMBAI -400 001</b>
<b>Company Code No. AUROPHARMA</b>	<b>Company Code No. 524804</b>

**Sub: Update on completion of sale/ transfer of API Non-Antibiotic Business and API Antibiotic Business to Apitoria Pharma Private Limited (formerly known as Auro Pharma India Private Limited), a wholly owned subsidiary of the Company - Information under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (SEBI LODR, Regulations)**

**Ref: Intimation dated February 9, 2023 in respect of sale/ transfer of API Non-Antibiotic Business and intimation dated April 1, 2023 in respect of sale/ transfer of API Antibiotic Business**

Dear Sir/Madam,

We refer to our letters dated February 9, 2023 and April 1, 2023 informing that the Company had entered into Business Transfer Agreements ("BTA") with Apitoria Pharma Private Limited (formerly known as Auro Pharma India Private Limited) (hereinafter referred to as "Apitoria"), a wholly-owned subsidiary of the Company for sale/transfer of the API Non-Antibiotic Business operated through its operating manufacturing plants, (Unit I, Unit VIII, Unit IX, Unit XI, Unit XIV (integrated unit) and R&D Unit 02) and API Antibiotic Business of the Company operated through its operating manufacturing plants, (Unit V & Unit XVII), respectively, (both excluding the land and buildings pertaining to the said divisions), as a going concern on slump sale basis.

In continuation to the above and in compliance with Regulation 30 and other applicable provisions of the SEBI LODR Regulations, we would like to inform that in terms of the respective BTAs, the sale/transfer of the Company's API Non-Antibiotic Business and API Antibiotic Business to Apitoria are complete on September 30, 2023 and consequently the API Non-Antibiotic Business and API Antibiotic Business shall be undertaken from Apitoria with effect from October 1, 2023.

Given that the key regulatory approvals in respect of the above business transfers were received on September 30, 2023, and the consequent restrictions to account the business transfer with effect from April 1, 2023, it is proposed to make the aforesaid business transfers effective from October 1, 2023.

Thanking you,

Yours faithfully,  
For **AUROBINDO PHARMA LIMITED**

B. Adi Reddy  
**Company Secretary**

**AUROBINDO PHARMA LIMITED**

(CIN : L24239TG1986PLC015190)

[www.aurobindo.com](http://www.aurobindo.com)

PAN No. AABCA7366H

Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad – 500 032, Telangana, India. Tel : +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044.

Regd.off.: Plot No. 2, Maithrivihar, Ameerpet, Hyderabad -500038 T.S., INDIA Tel: +91 40 2373 6370/2374 7340 Fax: +91 40 2374 1080/ 2374 6833